Fig. 4: Knockdown of SPI1 combined with erastin promotes ferroptosis in a ccRCC xenograft mouse model.
From: Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC
A Subcutaneous tumors of various treatment conditions were demonstrated. B, C The final tumor volume and weight were measured at 26-day. D The tumor volume of various treatment conditions was measured at 6, 12, 18 and 24 days. E qRT-PCR for mRNA expression of ACSL4 in tumors of nude mice treated with the corresponding conditions (n = 3). F Western bolt for protein expression of ACSL4 in tumors of nude mice treated with the corresponding conditions (n = 3). G, H Flow cytometry was used to detect lipid peroxidation level in the DMSO, Erastin, shSPI1+Erastin as well as shSPI1+Erastin+si-ACSL4 groups in tumors of nude mice (n = 3). Data are presented as the mean ± SD and analyzed by t -test or Kruskal-Wallis test. *: P < 0.05, **: P < 0.01, ***: P < 0.001.
